Invitrogen Files Patent Infringement Suit Against GE Healthcare | GenomeWeb
NEW YORK (GenomeWeb News) – Invitrogen last week filed a patent infringement suit against GE Healthcare and other unnamed defendants for allegedly infringing six patents, four of which expired earlier this year.
 
Invitrogen said in its complaint filed in the US District Court for the Eastern District of Texas Tyler Division that GE Healthcare’s CyScript reverse transcriptase enzymes and kits infringe all six of the patents.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.